investigational status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-15. Numbers and descriptions here follow the published literature rather than marketing material.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Extrinsic factors may also increase the risk of infection in those with cirrhosis, including proton pump inhibitor use, alcohol use, frailty, antibiotic overuse, and hospitalizations or invasive procedures (which increase the risk of bacterial translocation to other areas of the body). Infections that are common in those in the hospital with cirrhosis include spontaneous bacterial peritonitis (with a prevalence of 27% among hospitalized patients), urinary tract infections (22–29%), pneumonia (19%), spontaneous bacteremia (8–13%), skin and soft tissue infections (8-12%) and C. difficile colitis (2.4-4%). It is estimated that 3.5% of people with cirrhosis and ascites may have asymptomatic spontaneous bacterial peritonitis. The mortality rate for infections in those with cirrhosis is higher than that of the general population. In those with cirrhosis and severe infections with sepsis, the mortality rate is greater than 50%, and in those with septic shock, the mortality rate is 65%.
==== Monosaccharide reduction ==== There are many ways silver nanoparticles can be synthesized; one method is through monosaccharides. This includes glucose, fructose, maltose, maltodextrin, etc., but not sucrose. It is also a simple method to reduce silver ions back to silver nanoparticles as it usually involves a one-step process. There have been methods that indicated that these reducing sugars are essential to the formation of silver nanoparticles. Many studies indicated that this method of green synthesis, specifically using Cacumen platycladi extract, enabled the reduction of silver. Additionally, the size of the nanoparticle could be controlled depending on the concentration of the extract. The studies indicate that the higher concentrations correlated to an increased number of nanoparticles. Smaller nanoparticles were formed at high pH levels due to the concentration of the monosaccharides. Another method of silver nanoparticle synthesis includes the use of reducing sugars with alkali starch and silver nitrate. The reducing sugars have free aldehyde and ketone groups, which enable them to be oxidized into gluconate. The monosaccharide must have a free ketone group because in order to act as a reducing agent it first undergoes tautomerization. In addition, if the aldehydes are bound, it will be stuck in cyclic form and cannot act as a reducing agent. For example, glucose has an aldehyde functional group that is able to reduce silver cations to silver atoms and is then oxidized to gluconic acid. The reaction for the sugars to be oxidized occurs in aqueous solutions.
To ensure that the Presidency of Quito became a part of Gran Colombia and did not remain a collection of small, divided republics, Bolívar sent aid in the form of supplies and an army under Antonio José de Sucre to Guayaquil in February 1821. For a year Sucre was unable to take Quito, and by November both sides, exhausted, signed a ninety-day armistice. The following year, at the Battle of Pichincha on 24 May 1822, Sucre's Venezuelan forces finally conquered Quito; Gran Colombia's hold on the territory was secure. The following year, after a Peruvian Patriot army was destroyed in the Battle of Ica, San Martín met with Simón Bolívar in Guayaquil on 26 and 27 July. Thereafter San Martín decided to retire from the scene. For the next two years, two armies of Rioplatense (Argentinian), Chilean, Colombian and Peruvian Patriots were destroyed trying to penetrate the royalist bastion in the Andean regions of Peru and Upper Peru. A year later a Peruvian congress resolved to make Bolívar head of the Patriot forces in the country. An internecine conflict between La Serna and General Pedro Antonio Olañeta, which was an extension of the Liberal Triennium, proved to be the royalists' undoing. La Serna lost control of half of his best army by the beginning of 1824, giving the Patriots an opportunity.
=== Physical properties === Elemental magnesium is a gray-white lightweight metal, two-thirds the density of aluminium. Magnesium has the lowest melting (923 K (650 °C)) and the lowest boiling point (1,363 K (1,090 °C)) of all the alkaline earth metals. Pure polycrystalline magnesium is brittle and easily fractures along shear bands. It becomes much more malleable when alloyed with small amounts of other metals, such as 1% aluminium. The malleability of polycrystalline magnesium can also be significantly improved by reducing its grain size to about 1 μm or less.
Sources: en.wikipedia.org
Jake Carlisle (born 1 October 1991) is a former professional Australian rules footballer who played 66 games for the St Kilda Football Club in the Australian Football League (AFL) until his retirement at the end of the 2021 season. He previously played 85 games for the Essendon Football Club from 2010 to 2015.
=== Legal status === Tiratricol was once an approved medication in Brazil, but its marketing authorization was suspended in 2003. Tiratricol is available in France for therapy of thyroid hormone resistance and adjuvant therapy of thyroid cancer. In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Emcitate, intended for the treatment of MCT8 deficiency (Allan-Herndon-Dudley syndrome). The applicant for this medicinal product is Rare Thyroid Therapeutics International AB. Emcitate is a hybrid medicine of Téatrois, which has been authorized in France. Emcitate contains the same active substance as Téatrois but has a different indication. Tiratricol was authorized for medical use in the European Union in February 2025. Tiratricol was approved for medical use in the United States in September 2026. The US Food and Drug Administration (FDA) granted the application for tiratricol orphan drug, rare pediatric disease, fast track, breakthrough therapy, and priority review designations. The FDA granted the approval of Emcitate to Egetis Therapeutics US.
The chain's origin can be traced to the Dwarf Grill (now the Dwarf House), a restaurant opened by S. Truett Cathy (the chain's former chairman and CEO) in 1946 in the Atlanta suburb of Hapeville, Georgia. The original store was located near the Ford Motor Company Atlanta Assembly Plant, a source of many of the restaurant's patrons for years. It was later remodeled, reopening in 2022. In 1961, after 15 years in the fast-food business, Cathy found a pressure fryer that could cook a chicken sandwich in the same time it took to cook a hamburger. Following this discovery, he registered the name Chick-fil-A, Inc. The company's trademarked slogan, "We Didn't Invent the Chicken, Just the Chicken Sandwich," refers to their flagship menu item, the Chick-fil-A chicken sandwich. Though Chick-fil-A was the first national chain to make a fast, fried chicken sandwich its flagship item, it has been shown that Cathy's claim to have "invented the chicken sandwich" is false. From 1964 to 1967, the sandwich was licensed to over fifty eateries, including Waffle House and the concession stands of the new Houston Astrodome. The Chick-Fil-A sandwich was withdrawn from sale at other restaurants when the first dedicated location opened in 1967, in the food court of the Greenbriar Mall in Atlanta. The chain expanded in the 1970s and early 1980s by opening new locations in suburban malls' food courts. The first freestanding location was opened April 16, 1986, on North Druid Hills Road in Atlanta, Georgia, and the company began to focus more on stand-alone units rather than food courts.
Francis Pryor was supportive of the initiative and wrote afterwards: "happily, it was an experiment that worked: the participants had a good time, and the archaeology was professionally excavated, to a very high standard."
Adenylate cyclase manufactures cyclic adenosine monophosphate (cyclic AMP or cAMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which then phosphorylates glycogen phosphorylase b (PYG b), converting it into the active form called phosphorylase a (PYG a). Phosphorylase a is the enzyme responsible for the release of glucose 1-phosphate from glycogen polymers. An example of the pathway would be when glucagon binds to a transmembrane protein. The transmembrane proteins interacts with Gɑβ𝛾. Gαs separates from Gβ𝛾 and interacts with the transmembrane protein adenylyl cyclase. Adenylyl cyclase catalyzes the conversion of ATP to cAMP. cAMP binds to protein kinase A, and the complex phosphorylates glycogen phosphorylase kinase. Phosphorylated glycogen phosphorylase kinase phosphorylates glycogen phosphorylase. Phosphorylated glycogen phosphorylase clips glucose units from glycogen as glucose 1-phosphate. Additionally, the coordinated control of glycolysis and gluconeogenesis in the liver is adjusted by the phosphorylation state of the enzymes that catalyze the formation of a potent activator of glycolysis called fructose 2,6-bisphosphate. The enzyme protein kinase A (PKA) that was stimulated by the cascade initiated by glucagon will also phosphorylate a single serine residue of the bifunctional polypeptide chain containing both the enzymes fructose 2,6-bisphosphatase and phosphofructokinase-2. This covalent phosphorylation initiated by glucagon activates the former and inhibits the latter.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.